With the COVID-19 pandemic conditions improving in India according to some local reports, the demand for antiviral drugs Remdesivir and […]
A Korean pharmaceutical company will combine its pancreatitis investigational product called Foistar (DWJ1248) with Gilead’s remdesivir in a new Phase […]
A growing number of articles, papers and discussions point out that despite the great news of vaccines approved for emergency […]
Much attention was placed on the antiviral drug remdesivir during the early stages of the COVID-19 pandemic. In fact, considerable public […]
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institute of Health (NIH), recently produced results […]
This week, Eli Lilly and Company and Incyte announced the publication of the New England Journal of Medicine’s peer-reviewed results […]
The World Health Organization (WHO) advises against using Remdesivir under any circumstances. Apparently, a prominent group of intensive care doctors […]
In the early stages of the COVID-19 pandemic, those involved in monitoring new drugs that may help inhibit the SARS-CoV-2 […]
Keith Speights writes for investment advisory website Motley Fool and brings the eclectic and varied background TrialSite appreciates. Mr. Speight highlighted […]
Remdesivir has become a blockbuster drug in short time thanks in part to a pandemic-driven ACTIV-1 clinical trial and subsequent U.S. […]
